Doccla is a provider of virtual ward & remote monitoring company, who are partnering with Pfizer to support the elranatamabâ–¼/Doccla patient support programme.
Elranatamab is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
Elranatamab has a conditional marketing authorisation. A conditional marketing authorisation means that further evidence of efficacy and safety data are being collected. New information on this medicinal product will be reviewed when any relevant information of significance becomes available and at least every year. The licensing authority will review new information on this medicine at least every year and update the Summary of Product Characteristics as necessary.
For Elranatamab Prescribing Information for United Kingdom click here.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.